141 related articles for article (PubMed ID: 32152078)
1. ARGONAUT II Study of the
Jacobs MR; Good CE; Hujer AM; Abdelhamed AM; Rhoads DD; Hujer KM; Rudin SD; Domitrovic TN; Connolly LE; Krause KM; Patel R; Arias CA; Kreiswirth BN; Rojas LJ; D'Souza R; White RC; Brinkac LM; Nguyen K; Singh I; Fouts DE; van Duin D; Bonomo RA;
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32152078
[TBL] [Abstract][Full Text] [Related]
2. Nationwide epidemiology of carbapenem resistant Klebsiella pneumoniae isolates from Greek hospitals, with regards to plazomicin and aminoglycoside resistance.
Galani I; Nafplioti K; Adamou P; Karaiskos I; Giamarellou H; Souli M;
BMC Infect Dis; 2019 Feb; 19(1):167. PubMed ID: 30770727
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of plazomicin against β-lactamase-producing carbapenem-resistant Enterobacteriaceae (CRE).
Zhang Y; Kashikar A; Bush K
J Antimicrob Chemother; 2017 Oct; 72(10):2792-2795. PubMed ID: 29091224
[TBL] [Abstract][Full Text] [Related]
4.
Castanheira M; Davis AP; Mendes RE; Serio AW; Krause KM; Flamm RK
Antimicrob Agents Chemother; 2018 Aug; 62(8):. PubMed ID: 29866862
[TBL] [Abstract][Full Text] [Related]
5. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
[TBL] [Abstract][Full Text] [Related]
6. Distribution of genes encoding 16S rRNA methyltransferase in plazomicin-nonsusceptible carbapenemase-producing Enterobacterales in Brazil.
Bail L; Ito CAS; Arend LNVS; Pilonetto M; Nogueira KDS; Tuon FF
Diagn Microbiol Infect Dis; 2021 Feb; 99(2):115239. PubMed ID: 33130509
[TBL] [Abstract][Full Text] [Related]
7. Antimicrobial activity of plazomicin against Enterobacteriaceae-producing carbapenemases from 50 Brazilian medical centers.
Martins AF; Bail L; Ito CAS; da Silva Nogueira K; Dalmolin TV; Martins AS; Rocha JLL; Serio AW; Tuon FF
Diagn Microbiol Infect Dis; 2018 Mar; 90(3):228-232. PubMed ID: 29223516
[TBL] [Abstract][Full Text] [Related]
8. Activity of plazomicin compared with other aminoglycosides against isolates from European and adjacent countries, including Enterobacteriaceae molecularly characterized for aminoglycoside-modifying enzymes and other resistance mechanisms.
Castanheira M; Deshpande LM; Woosley LN; Serio AW; Krause KM; Flamm RK
J Antimicrob Chemother; 2018 Dec; 73(12):3346-3354. PubMed ID: 30219857
[TBL] [Abstract][Full Text] [Related]
9. Carbapenem-resistant Klebsiella pneumoniae strains exhibit diversity in aminoglycoside-modifying enzymes, which exert differing effects on plazomicin and other agents.
Almaghrabi R; Clancy CJ; Doi Y; Hao B; Chen L; Shields RK; Press EG; Iovine NM; Townsend BM; Wagener MM; Kreiswirth B; Nguyen MH
Antimicrob Agents Chemother; 2014 Aug; 58(8):4443-51. PubMed ID: 24867988
[TBL] [Abstract][Full Text] [Related]
10. Expected plazomicin susceptibility in India based on the prevailing aminoglycoside resistance mechanisms in Gram-negative organisms derived from whole-genome sequencing.
Pragasam AK; Jennifer SL; Solaimalai D; Muthuirulandi Sethuvel DP; Rachel T; Elangovan D; Vasudevan K; Gunasekaran K; Veeraraghavan B
Indian J Med Microbiol; 2020; 38(3 & 4):313-318. PubMed ID: 33154241
[TBL] [Abstract][Full Text] [Related]
11. Comparative in vitro activity of plazomicin and older aminoglyosides against Enterobacterales isolates; prevalence of aminoglycoside modifying enzymes and 16S rRNA methyltransferases.
Gür D; Hasdemir U; Çakar A; Çavuşoğlu İ; Çelik T; Aksu B;
Diagn Microbiol Infect Dis; 2020 Aug; 97(4):115092. PubMed ID: 32569921
[TBL] [Abstract][Full Text] [Related]
12. In vitro activity of plazomicin compared to other clinically relevant aminoglycosides in carbapenem-resistant Enterobacteriaceae.
Clark JA; Kulengowski B; Burgess DS
Diagn Microbiol Infect Dis; 2020 Oct; 98(2):115117. PubMed ID: 32755805
[TBL] [Abstract][Full Text] [Related]
13. Emergence of co-existence of bla
Kiaei S; Moradi M; Hosseini Nave H; Hashemizadeh Z; Taati-Moghadam M; Kalantar-Neyestanaki D
Folia Microbiol (Praha); 2019 Jan; 64(1):55-62. PubMed ID: 30003527
[TBL] [Abstract][Full Text] [Related]
14. Comparative evaluation of plazomicin MICs obtained using agar dilution versus broth microdilution methods and impact of inoculum size against ESBL-producing Escherichia coli, carbapenemase-producing Klebsiella pneumoniae and methicillin-resistant Staphylococcus aureus clinical isolates.
Emiliov T; Rodríguez-Avial I; López-Diaz MDC; Culebras E
Diagn Microbiol Infect Dis; 2019 Nov; 95(3):114867. PubMed ID: 31402069
[TBL] [Abstract][Full Text] [Related]
15. Plazomicin activity against polymyxin-resistant Enterobacteriaceae, including MCR-1-producing isolates.
Denervaud-Tendon V; Poirel L; Connolly LE; Krause KM; Nordmann P
J Antimicrob Chemother; 2017 Oct; 72(10):2787-2791. PubMed ID: 29091226
[TBL] [Abstract][Full Text] [Related]
16. In vitro and in vivo bactericidal activity of ceftazidime-avibactam against Carbapenemase-producing
Zhang W; Guo Y; Li J; Zhang Y; Yang Y; Dong D; Zhu D; He P; Hu F
Antimicrob Resist Infect Control; 2018; 7():142. PubMed ID: 30479755
[TBL] [Abstract][Full Text] [Related]
17. In vitro activity of cefiderocol, a siderophore cephalosporin, against a recent collection of clinically relevant carbapenem-non-susceptible Gram-negative bacilli, including serine carbapenemase- and metallo-β-lactamase-producing isolates (SIDERO-WT-2014 Study).
Kazmierczak KM; Tsuji M; Wise MG; Hackel M; Yamano Y; Echols R; Sahm DF
Int J Antimicrob Agents; 2019 Feb; 53(2):177-184. PubMed ID: 30395986
[TBL] [Abstract][Full Text] [Related]
18. Activity of Plazomicin Tested against
Castanheira M; Sader HS; Mendes RE; Jones RN
Antimicrob Agents Chemother; 2020 Apr; 64(5):. PubMed ID: 32094137
[TBL] [Abstract][Full Text] [Related]
19. High prevalence of 16S rRNA methyltransferases among carbapenemase-producing Enterobacteriaceae in the UK and Ireland.
Taylor E; Sriskandan S; Woodford N; Hopkins KL
Int J Antimicrob Agents; 2018 Aug; 52(2):278-282. PubMed ID: 29596903
[TBL] [Abstract][Full Text] [Related]
20. In vitro activity of plazomicin against 5,015 gram-negative and gram-positive clinical isolates obtained from patients in canadian hospitals as part of the CANWARD study, 2011-2012.
Walkty A; Adam H; Baxter M; Denisuik A; Lagacé-Wiens P; Karlowsky JA; Hoban DJ; Zhanel GG
Antimicrob Agents Chemother; 2014 May; 58(5):2554-63. PubMed ID: 24550325
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
